Bendamustine Products — CPB 0875 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0875 governing bendamustine coverage policy, effective February 25, 2026. Billing teams treating hematologic malignancies need to review updated combination therapy requirements before submitting claims for J9033, J9034, J9036, and J9056.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Bendamustine Products — CPB 0875
Policy Code	CPB 0875
Change Type	Modified
Effective Date	February 25, 2026
Impact Level	High
Specialties Affected	Hematology/Oncology, Infusion Centers, Hospital Outpatient, Specialty Pharmacy
Key Action	Verify combination therapy requirements and prior authorization status before billing J9033, J9034, J9036, or J9056 for any lymphoma subtype

---

Aetna Bendamustine Coverage Criteria and Medical Necessity Requirements 2026

Aetna CPB 0875 governs coverage of bendamustine products — Belrapzo, Bendeka, Treanda, Vivimusta, and generic bendamustine — for commercial medical plan members. This is not a simple "is bendamustine covered" question. The answer depends entirely on the specific lymphoma subtype and the exact combination regimen your physician ordered.

Precertification is required across the board. Call (866) 752-7021 or fax (888) 267-3277 before treatment starts. Missing prior authorization on these claims is the fastest path to a claim denial, and with drug costs on bendamustine regimens potentially running into thousands of dollars per infusion, the financial exposure on a denial is significant.

Medical Necessity: B-Cell Lymphoma

Aetna's coverage policy for B-cell lymphoma is the most complex section of CPB 0875. Coverage is not blanket approval for bendamustine in B-cell disease — each subtype carries its own requirements.

Diffuse large B-cell lymphoma (DLBCL) — including HIV-related DLBCL, primary effusion lymphoma, HHV8-positive DLBCL, plasmablastic lymphoma, high-grade B-cell lymphoma, and monomorphic post-transplant lymphoproliferative disorders — requires two conditions: the drug must be used as subsequent therapy, and it must be combined with polatuzumab vedotin-piiq (J9309) with or without rituximab (J9312). First-line use in DLBCL does not meet medical necessity under this policy.

Follicular lymphoma gets broader coverage. Based on the available policy summary data, bendamustine does not require a specific combination partner for follicular lymphoma — but verify this against the full CPB 0875 document before billing, as the policy summary provided is truncated.

Histologic transformation of indolent lymphomas to DLBCL carries three simultaneous requirements. The member must have received prior anthracycline-based therapy (for example, doxorubicin, billed as J9000). They must not be a transplant candidate. And bendamustine must be combined with polatuzumab vedotin-piiq with or without rituximab. All three boxes have to be checked.

Mantle cell lymphoma (MCL) has more flexibility than DLBCL. Aetna covers bendamustine in MCL when used with rituximab alone, as part of the RBAC500 regimen (rituximab, bendamustine, and cytarabine — J9100), or in combination with acalabrutinib and rituximab.

Marginal zone lymphoma — nodal, extranodal gastric (MALT), extranodal nongastric, and splenic subtypes — all require combination with either rituximab (J9312) or obinutuzumab (J9301). Monotherapy with bendamustine in marginal zone lymphoma does not satisfy the coverage policy criteria.

Medical Necessity: T-Cell Lymphoma

The policy summary for T-cell lymphoma was truncated in the available data. If your practice treats adult T-cell leukemia/lymphoma (ATLL) or other T-cell subtypes, pull the full CPB 0875 document from Aetna directly and verify the exact criteria before billing. Do not assume T-cell coverage mirrors B-cell criteria — it almost certainly does not.

The Combination Therapy Problem

The real issue here is documentation alignment. Aetna's coverage policy for most DLBCL subtypes and high-grade B-cell lymphomas hinges on a specific combination partner: polatuzumab vedotin-piiq (J9309). If your claim for J9033, J9034, J9036, or J9056 doesn't also include J9309 — and the medical record doesn't support it — you're looking at a medical necessity denial.

Your billing team needs to understand this isn't just a formulary issue. It's a coding and documentation issue.

---

Aetna Bendamustine Exclusions and Non-Covered Indications

Based on the available policy data, Aetna does not cover bendamustine as monotherapy for DLBCL subtypes. First-line bendamustine for DLBCL, high-grade B-cell lymphoma, and HIV-related B-cell lymphoma falls outside medical necessity criteria — subsequent therapy is required.

Histologic transformation cases where the member is a transplant candidate also do not meet coverage criteria under CPB 0875. If transplant eligibility is in question, document the clinical rationale clearly before submitting.

For marginal zone lymphoma, bendamustine without rituximab or obinutuzumab is not covered. Monotherapy claims will be denied.

The full exclusion list for conditions like chronic lymphocytic leukemia (CLL), multiple myeloma, and other indications referenced in the broader CPB 0875 policy should be reviewed directly. The truncated policy summary suggests additional indications — and additional exclusions — beyond what's captured here.

---

Coverage Indications at a Glance

---

Aetna Bendamustine Billing Guidelines and Action Items 2026

The effective date of February 25, 2026 means this policy is active now. If your team hasn't adjusted workflows yet, do it this week.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Bendamustine Under CPB 0875

Bendamustine HCPCS Codes (Primary Billing Codes)

Additional HCPCS Codes Listed in CPB 0875

These codes appear in the policy alongside bendamustine. Some — like J9309 (polatuzumab vedotin-piiq), J9312 (rituximab), J9301 (obinutuzumab), and J9100 (cytarabine) — are explicitly required as combination partners for specific indications as described above. Others are listed in the policy without explicit characterization as combination requirements. Confirm the clinical context for each code against the full CPB 0875 document before drawing conclusions about coverage requirements.

Supportive Agent HCPCS Codes

Chemotherapy Administration CPT Codes

Code	Type	Description Copy
96413	CPT	Chemotherapy administration, IV infusion; up to 1 hour, single or initial substance
96415	CPT	Chemotherapy administration, IV infusion; each additional hour

Bone Marrow and Stem Cell Services CPT Codes

ICD-10-CM Diagnosis Codes

The full CPB 0875 policy includes 352 ICD-10-CM codes. The source policy data includes the codes below. Their clinical context within CPB 0875 should be confirmed against the full policy document — do not assume all listed ICD-10 codes correspond to covered bendamustine indications.

Note: The ICD-10 code set for this policy is extensive. Lymphoma-specific codes (C82–C86 series for follicular, diffuse large B-cell, mantle cell, marginal zone, and T-cell lymphomas) are included in the full policy but exceeded the data extract above. Pull the complete diagnosis code list from the source policy before finalizing charge capture mappings.

---